These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7571543)

  • 1. [Rational basis for development of a treatment program for Parkinson's disease].
    Jovicić A; Dordević D; Raicević R; Marić D; Jovanović M
    Vojnosanit Pregl; 1995; 52(3):253-60. PubMed ID: 7571543
    [No Abstract]   [Full Text] [Related]  

  • 2. [Rational approach to drug therapy is the basis for life quality management in patients with Parkinson's disease].
    Litvinenko IV; Odinak MM
    Voen Med Zh; 2004 Apr; 325(4):47-53. PubMed ID: 15188541
    [No Abstract]   [Full Text] [Related]  

  • 3. Designing neuroprotection trials in Parkinson's disease.
    Kieburtz K
    Ann Neurol; 2003; 53 Suppl 3():S100-7; discussion S107-9. PubMed ID: 12666102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational management of the 'on-off' syndrome in Parkinson's disease.
    Coleman RJ
    Q J Med; 1990 Feb; 74(274):121-31. PubMed ID: 2189148
    [No Abstract]   [Full Text] [Related]  

  • 5. "Rational hope" in the early treatment of Parkinson's disease.
    Sourkes TL
    Can J Physiol Pharmacol; 1999 Jun; 77(6):375-82. PubMed ID: 10537223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the Parkinson's disease medication protocol program on nurses' knowledge and management of Parkinson's disease medicines in acute and aged care settings.
    Chenoweth L; Sheriff J; McAnally L; Tait F
    Nurse Educ Today; 2013 May; 33(5):458-64. PubMed ID: 22626862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The recent advance of treatment of Parkinson's disease].
    Matsubara E
    Nihon Rinsho; 2004 Sep; 62(9):1725-8. PubMed ID: 15462392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The history of drugs for the treatment of Parkinson's disease.
    Kapp W
    J Neural Transm Suppl; 1992; 38():1-6. PubMed ID: 1491242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances and challenges in the dosage form design for the treatment of Parkinson's disease.
    Wen MM
    Discov Med; 2012 Dec; 14(79):369-77. PubMed ID: 23272689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modern therapy of Parkinson's disease.
    Ransmayr G; Künig G; Gerstenbrand F
    J Neural Transm Suppl; 1992; 38():129-40. PubMed ID: 1491245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiological, genetic, pharmacological, kinesiological, nuclear medical (IBZM-SPECT), standard and functional MRI studies on Parkinson's disease and related disorders and economic evaluation of Parkinson's disease therapy--clinical projects in the BMFT-research program Munich: "Parkinson's disease and other basal ganglia disorders".
    Oertel WH; Trenkwalder C; Gasser T; Schwarz J; Bucher SF; Eichhorn T; Pogarell O; Künig G; Arnold G; Bandmann O
    J Neural Transm Suppl; 1995; 46():325-37. PubMed ID: 8821069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advance in studies on pathological mechanism of Parkinson's disease and traditional Chinese medicine experiments in prevention and treatment of Parkinson's disease].
    Xiong P; Chen X; Zhang N
    Zhongguo Zhong Yao Za Zhi; 2012 Mar; 37(5):686-91. PubMed ID: 22693916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of Parkinson's disease with multiple drugs].
    Kuno S
    Nihon Rinsho; 1997 Jan; 55(1):59-64. PubMed ID: 9014424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fat-soluble vitamin therapy in senile dementia and Parkinson's disease].
    Nakashima K; Takahashi K
    Nihon Rinsho; 1993 Apr; 51(4):1017-22. PubMed ID: 8483257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neuroplasticity and Parkinson disease].
    Viallet F; Witjas T
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S42-8. PubMed ID: 12690663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
    Cools R
    Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of early Parkinson's disease.
    Pahwa R; Lyons KE
    Curr Opin Neurol; 2014 Aug; 27(4):442-9. PubMed ID: 24950010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy of Parkinson's disease.
    Cohen MM; Scheife RT
    Am J Hosp Pharm; 1977 May; 34(5):531-8. PubMed ID: 326045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What has been learnt from study of dopamine receptors in Parkinson's disease?
    Hurley MJ; Jenner P
    Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.